Shionogi: Pipeline, Products, Performance, Potential

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Financial Performance 2005
  • Sales and Market Position
  • Income
    • Sales, Costs and Operating Income
  • Expenditure
    • Capital Expenditure
    • Capital Expenditure by Business Area
    • Capital Expenditure by Business Area, 2005
    • R&D Expenditure
    • R&D Expenditure and Capital Expenditure
  • Divisional Performance
    • Sales by Business Area
    • Sales by Business Area
    • Operating Income by Business Area
    • Operating Income by Business Area
    • Total Assets by Business Area
    • Total Assets by Business Area, 2005
  • Geographic Performance
• Company Strategy
  • Financial Targets (Consolidated)
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
• Product/R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • R&D Pipeline Overview
    • Discontinued R&D Projects
  • Sales Forecast
    • Sales of Major Products (2000A-2010E)
• Conclusions

PRODUCT PORTFOLIO/RESEARCH AND DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• Sales of Major Products, 2005
• R&D Pipeline

• Antibiotic - Products
  • Major Launched Products
  • Finibax
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Sales Forecast
    • Clinical Trials
  • Flomox
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Flomox Sales (2000A-2010E)
  • Flumarin
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Flumarin Sales (2000A-2010E)
  • Kefral
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Kefral Sales (2000A-2010E)
  • Vancomycin
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Vancomycin Sales (2000A-2010E)
  • Avelox (BAY 12-8039)
  • Seftem/Cedax
• Antibiotic - R&D
  • S-013420
• Antibiotic - Summary
  • Growth Potential
  • Limiting Factors
• Circulatory and Respiratory System - Products
  • Major Launched Products
  • Claritin
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
  • Claritin Sales (2000A-2010E)
  • Crestor
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Safety Issues
    • Sales Forecast
    • Clinical Trial Results
  • Dobutrex
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Dobutrex Sales (2000A-2010E)
  • Longes
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Sales Forecast
  • Longes Sales (2000A-2010E)
  • Landel
• Circulatory and Respiratory System - R&D
  • Irbesartan
  • Pirfenidone
    • Clinical Trial Results
  • S-0139
  • S-5751
• Circulatory and Respiratory System - Summary
  • Growth Potential
  • Limiting Factors
• Anticancer - Products
  • Major Launched Products
  • Imunace
    • Sales
    • Key Markets/Indications/Formulations
    • Sales Forecast
  • Imunace Sales (2000A-2010E)
  • Uromitexan
  • Aqupla
• Anticancer - R&D
  • Cetrorelix
• Anticancer - Summary
  • Growth Potential
  • Limiting Factors
• Central Nervous System - Products
  • Major Launched Products
  • MS Contin
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Sales Forecast
  • MS Contin Sales (2000A-2010E)
  • OxyContin
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Sales Forecast
  • Oxycontin Sales (2000A-2010E)
  • Morphine Hydrochloride (MH-200/MH-15E)
  • Others
• Central Nervous System - R&D
  • Duloxetine (LY248686)
  • S-0373
• Central Nervous System - Summary
  • Growth Potential
  • Limiting Factors
• Other - Products
  • Ulgut
  • Tamiflu
  • Fulmeta
  • Hormone Products
  • Biological Products
• Other - R&D
  • Cetrorelix
  • S-2367

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• AstraZeneca
  • 16th May 2002
• Bayer
  • 17th October 2005
• Bristol-Myers Squibb/sanofi-aventis
  • May 1996
• Eli Lilly
• Enanta Pharmaceuticals Inc
  • 27th July 2004
  • 14th March 2005
  • 20th December 2005
• GlaxoSmithKline
  • 19th October 2001
  • 1st April 2003
• Kyowa Hakko Kogyo Ltd
  • 17th October 2002
• Marnac Inc/KDL Inc
  • 5th November 1996
• Peninsula Pharmaceuticals Inc
  • 26th May 2003
• MundiPharma BV
• Purdue Pharma LP
  • 10th January 2006
• Roche
  • 22nd January 2001
• Schering-Plough
  • 19th January 2001
  • 16th November 2004
• Licensing

• Discontinued Agreements
  • Pfizer
    • 1st July 2005

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - MAJOR PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES

• Subsidiaries
  • Domestic Wholly-Owned Subsidiaries
  • Overseas Wholly-Owned Subsidiaries
• Joint-Venture Companies

APPENDIX 6 - PRODUCT INDEX